Qiagen gets US FDA nod for therascreen KRAS kit as companion diagnostic test to Mirati Therapeutics Krazati in NSCLC
By, Admin1 min read
Share
Qiagen has announced the US Food and Drug Administration (FDA) approval of its therascreen KRAS RGQ PCR kit (therascreen KRAS kit) as a companion diagnostic test to Mirati Therapeutic
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
